外周T细胞淋巴瘤诊疗进展张智慧技术分析.ppt

Brentuximab Vedotin + 化疗一线治疗ALCL I 期临床试验: 39 pts 高危ALCL (IPI ≥ 2) or CD30+ 成熟T-cell/NK-细胞淋巴瘤 随机分为3组 1.8 mg/kg brentuximab vedotin q3w X 2 cycles, then CHOP x 6 cycles 1.8 mg/kg brentuximab vedotin + CHP q3w for up to 6 cycles Determine optimal dose of brentuximab vedotin to be used in combination with CHP in third arm Responders receive additional cycles of brentuximab vedotin monotherapy ORR: 100% (26/26); CR: 88% (23/26) Brentuximab vedotin MTD not exceeded at 1.8 mg/kg 1 DLT: grade 3 rash in 6 pts 治疗相关并发症: 恶心(58%), 疲乏 (50%), 腹泻(50%), 周围神经病变 (38%), 脱发(38%) Fanale MA, et al. ASH 2012. Abst